In this article
Early Detection of Gynecological Cancers
Pap smears can help reduce the incidence of cervical cancer. A new study shows that they can also be used to detect other gynecological cancers early. The tissue and fluid collected during the Pap smear can be genetically detected to detect endometrial and ovarian cancer. Researcher Dr. Amanda Fader said that if cancers are detected, thousands of lives can be saved each year by catching these cancers at an earlier and more treatable stage.
Genetic Detection of Tumor Mutations
The main goal is to be able to detect these cancers through mutations in tumor genes, which are usually found in the blood or fluids collected from the cervix and vagina. If we can detect cancer in the early or early stages of cancer, not only is it possible to get more treatment, but it will also protect many women from having more fertility.
In a Pap smear, the doctor uses a spatula or brush to collect cells from the cervix, which are then sent to the laboratory for analysis.
PapSEEK: Study Methodology and Accuracy
The researchers developed a test protocol called PapSEEK to see if other samples collected during the pelvic exam can be used to detect endometrial cancer or ovarian cancer. PapSEEK can detect DNA mutations that have been identified as specific cancers, including 18 commonly mutated genes.
To see if the test worked, the researchers collected samples from 1,658 women, 656 of whom had endometrial or ovarian cancer, and 1,000 healthy women as a control group. Studies have shown that the PapSEEK test can accurately detect 81% of endometrial cancers and 33% of ovarian cancers. When the researchers used brushes to collect samples, accurate detection increased to 93% and 45%, respectively.
This is a very early preliminary result and looks promising, but there is still a long way to go to determine whether this is really useful.
For details on cervical cancer treatment and second opinion, do call us at +91 96 1588 1588 or write to [email protected].
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.